VolitionRx Limited (NYSE American: VNRX) has highlighted a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis. The company released an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter, underscoring the potential of its Nu.Q H3.1 test in clinical settings.
Multiple studies have demonstrated that the Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity, and provide strong prognostic value for outcomes including organ failure and mortality. Most of the supporting research has been peer reviewed and published, with experts noting the consistency of findings across multiple countries and patient populations.
Volition believes its low-cost nucleosome quantification technology could help personalize patient care by identifying elevated H3.1 nucleosome levels as a treatable trait in sepsis management and informing future therapeutic strategies. The company is dedicated to advancing the science of epigenetics through its subsidiaries, developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.
The implications of this announcement are significant for the medical community and patients. Sepsis remains a leading cause of death worldwide, and early detection and monitoring are critical for improving outcomes. The Nu.Q NETs test could provide a valuable tool for clinicians to quickly identify sepsis and tailor treatments accordingly, potentially reducing mortality and organ failure rates. For the healthcare industry, this technology could lead to more efficient use of resources by enabling earlier intervention and personalized care.
For further information about Volition and its technologies, visit the company's website at https://volition.com/. The full press release can be viewed at https://ibn.fm/2IH3m.
VolitionRx is a multinational company focused on saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Its research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
